Emily K. Sims

358 posts

Emily K. Sims

Emily K. Sims

@EmKSims

Physician scientist at Indiana University

Indianapolis, IN شامل ہوئے Haziran 2018
172 فالونگ689 فالوورز
Emily K. Sims
Emily K. Sims@EmKSims·
3. Risk scores like HbA1c and metabolic indices performed better in adults 4. Unique patterns suggest a need for age-tailored screening and follow-up
English
1
0
6
653
Emily K. Sims
Emily K. Sims@EmKSims·
2. Unlike those were were single Ab positive or met stage 1 T1D criteria, adults with stage 2 T1D at screening progressed at the same rate as children (78% in 5 years)
English
0
0
3
276
Emily K. Sims
Emily K. Sims@EmKSims·
We found important differences exist in screening and progression amongst children and adults. For example: 1. Adults were more likely to screen single Ab positive compared to kids
English
1
0
3
355
Emily K. Sims
Emily K. Sims@EmKSims·
Super excited this paper on islet autoantibody positive adults is finally online- we analyzed screening and #T1D progression in 100K adult relatives screened as part of @T1D_TrialNet . Available at: bit.ly/4md4scn
English
3
5
13
1.4K
Emily K. Sims
Emily K. Sims@EmKSims·
Really excited to share this super translational project from rockstar @chaipoorva ! Islets and T cells and EVs- what more could you want ❤️?
Diabetologia@DiabetologiaJnl

Beta cell extracellular vesicles carry PD-L1 and suppress CD8+ T cells. EV PD-L1 is increased in AAB+ individuals, correlating with residual beta cell function. Potential #biomarker for #T1D heterogeneity. #Diabetes @IUSweetTweets @emksims @chaipoorva tinyurl.com/4pe2hbvb

English
1
5
22
2.3K
Emily K. Sims
Emily K. Sims@EmKSims·
Great work by @JacobsenLM and @Heba_T1D supporting the idea that metabolic endpoints can give us a quick readout of T1D disease modification. And we know based on @DrPeteTaylor and Colin Dayan's data that these changes have clinical relevance for our patients with T1D!
Diabetes Care, an ADA research journal 🌟@DiabetesCareADA

@T1D_TrialNet identifies earlier trial end points that demonstrate a beneficial treatment effect at 6 months and predict benefit out to 12 months. This could allow for shorter early phase trials or adaptive designs. @ADA_Pubs Read Here➡️doi.org/10.2337/dc24-0…

English
0
0
7
582
Rachel Besser
Rachel Besser@BesserBesser·
A trip to London, and I saw this on the tube, thoughts?! #T1diabetes
Rachel Besser tweet media
English
7
2
30
2.4K
Emily K. Sims
Emily K. Sims@EmKSims·
Do metabolic measures perform similarly for predicting T1D vs. assessing immunotherapy? Not necessarily. However, combined glucose and C-peptide measures were consistent performers for both purposes. Check out at bit.ly/482qeIc ! @T1D_TrialNet @IUSweetTweets
Emily K. Sims tweet media
English
0
1
7
606